Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 52, Issue 11, 2013, Pages 2048-2055

  Tydén, Helena ^a   Lood, Christian ^a   Gullstrand, Birgitta ^a   Jönsen, Andreas ^a   Nived, Ola ^a   Sturfelt, Gunnar ^a   Truedsson, Lennart ^a   Ivars, Fredrik ^b   Leanderson, Tomas ^b   Bengtsson, Anders A ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Calprotectin; Cardiovascular disease; EN RAGE; S100A12; S100A8 A9; Systemic lupus erythematosus

Indexed keywords

CALCIUM BINDING PROTEIN; CALGRANULIN A; CALGRANULIN B; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; PROTEIN S100A12; UNCLASSIFIED DRUG;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DIGESTIVE SYSTEM INJURY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; JOINT INJURY; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MUSCLE INJURY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REMISSION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM;

CALPROTECTIN; CARDIOVASCULAR DISEASE; EN-RAGE; S100A12; S100A8/A9; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALGRANULIN A; CALGRANULIN B; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; S100 PROTEINS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84886313953     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket263     Document Type: Article

References (49)

1. Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54: 2550-7.
2. Bjornadal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004;31: 713-9.
3. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
4. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
5. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
6. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67.
7. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-93.
8. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46.
9. Hayakawa E, Yoshimoto T, Sekizawa N, et al. Overexpression of receptor for advanced glycation end products induces monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cell line. J Atheroscler Thromb 2012;19:13-22.
10. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-97.
11. Schmidt AM, Hofmann M, Taguchi A, et al. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 2000;26:485-93.
12. Bjork P, Bjork A, Vogl T, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009;7:e97.
13. Eggers K, Sikora K, Lorenz M, et al. RAGE-dependent regulation of calcium-binding proteins S100A8 and S100A9 in human THP-1. Exp Clin Endocrinol Diabetes 2011;119:353-7.
14. Vogl T, Gharibyan AL, Morozova-Roche LA. Pro-inflammatory S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexes. Int J Mol Sci 2012;13:2893-917.
15. Pietzsch J, Hoppmann S. Human S100A12: a novel key player in inflammation?. Amino Acids 2009;36:381-9.
16. van Lent PL, Grevers L, Blom AB, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 2008;67:1750-8.
17. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13: 1042-9.
18. Loser K, Vogl T, Voskort M, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 2010;16: 713-7.
19. Yang Z, Tao T, Raftery MJ, et al. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001;69:986-94.
20. Katashima T, Naruko T, Terasaki F, et al. Enhanced expression of the S100A8/A9 complex in acute myocardial infarction patients. Circ J 2010;74:741-8.
21. Miyamoto S, Ueda M, Ikemoto M, et al. Increased serum levels and expression of S100A8/A9 complex in infiltrated neutrophils in atherosclerotic plaque of unstable angina. Heart 2008;94:1002-7.
22. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006;113:2278-84.
23. Saito T, Hojo Y, Ogoyama Y, et al. S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circ J 2012;76:2647-52.
24. Mori Y, Kosaki A, Kishimoto N, et al. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009;29:18-24.
25. Foell D, Kane D, Bresnihan B, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 2003;42: 1383-9.
26. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004;50: 3762-71.
27. Ehrchen JM, Sunderkotter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009;86:557-66.
28. Qi Y, Gong F, Zhang Q, et al. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease. Arthritis Res Ther 2012;14:R251.
29. Haga HJ, Brun JG, Berntzen HB, et al. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus 1993;2:47-50.
30. Soyfoo MS, Roth J, Vogl T, et al. Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol 2009;36:2190-4.
31. Lood C, Stenstrom M, Tyden H, et al. Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. Arthritis Res Ther 2011;13:R60.
32. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
33. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
34. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989;68:141-50.
35. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
36. Vikerfors A, Johansson AB, Gustafsson JT, et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology 2013;52: 501-9.
37. Hughes G. Hughes syndrome: the antiphospholipid syndrome- a clinical overview. Clin Rev Allergy Immunol 2007;32:3-12.
38. Hessian PA. Edgeworth J, Hogg N. MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes. J Leukoc Biol 1993;53:197-204.
39. Dell'Angelica EC, Schleicher CH, Santome JA. Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J Biol Chem 1994;269:28929-36.
40. Rammes A, Roth J, Goebeler M, et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997; 272:9496-502.
41. Urban CF, Ermert D, Schmid M, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 2009;5:e1000639.
42. Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93-6.
43. Nived O, Jonsen A, Bengtsson AA, et al. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002;29:1398-400.
44. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
45. Hofmann Bowman MA, Gawdzik J, Bukhari U, et al. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol 2011;31:33744.
46. Ehlermann P, Eggers K, Bierhaus A, et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol 2006;5:6.
47. Harja E, Bu DX, Hudson BI, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE -/- mice. J Clin Invest 2008;118:183-94.
48. Bjorkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipol 2006;17:527-33.
49. Hollan I, Scott H, Saatvedt K, et al. Inflammatory rheumatic disease and smoking are predictors of aortic inflammation: a controlled study of biopsy specimens obtained at coronary artery surgery. Arthritis Rheum 2007;56:2072-9.